Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of Emraclidine in Schizophrenia
NCT05443724Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of emraclidine in schizophrenia, sponsored by AbbVie Inc.. Started Sep 2022; status: terminated.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05443724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05443724.